Viant Medical appears to be a strategic enabler in the potential partnership between Electrome and BioElectronics Corporation (BIEL), with Sree Koneru serving as the connective tissue across all three entities. His dual role at Viant and BIEL strengthens the case for collaboration.
Viant’s Strategic Role in a BIEL–Electrome Partnership
1. Contract Manufacturing Backbone
Viant is a leading contract manufacturer specializing in wearable and implantable medical devices. With ISO-certified facilities and expertise in Class I–III devices, Viant could:
Manufacture next-gen versions of BIEL’s ActiPatch or RecoveryRx devices.
Support Electrome’s scale-up with clean-room assembly, smart sensor integration, and flexible form factors.
2. Leadership Synergy via Sree Koneru
Koneru is currently Director of Program Management at Viant and also sits on BIEL’s Board of Directors. This dual role enables:
Seamless communication between engineering, regulatory, and executive teams.
Strategic alignment on product modernization, cost optimization, and clinical validation.
3. Technology Modernization Pathway
Viant’s capabilities could help BIEL and Electrome co-develop:
A smartphone-powered, battery-free, ultra-flexible version of RecoveryRx.
Devices inspired by recent PRFE bandage research, but with FDA-cleared foundations.
4. Equity and Investment Potential
Some investor speculation suggests Viant could become an equity stakeholder in BIEL, especially as BIEL trades near historical lows. This opens doors for:
Strategic investment by Electrome or Viant.
Joint ventures targeting global reimbursement markets and retail expansion.
5. Clinical and Regulatory Acceleration
Viant’s infrastructure supports:
Faster FDA and CE submissions.
Efficient clinical trial execution, especially for neuromodulation technologies.
6. Partnership Scenario: Triangular Collaboration
BIEL
IP holder and product originator
FDA-cleared tech, clinical data
Electrome
Innovation and market expansion
New applications, branding, distribution
Viant
Manufacturing and engineering partner
Scale-up, modernization, regulatory support
Sree Koneru acts as the linchpin, connecting technical, regulatory, and strategic dots across all three.
Viant’s Strategic Role in a BIEL–Electrome Partnership
1. Contract Manufacturing Backbone
Viant is a leading contract manufacturer specializing in wearable and implantable medical devices. With ISO-certified facilities and expertise in Class I–III devices, Viant could:
Manufacture next-gen versions of BIEL’s ActiPatch or RecoveryRx devices.
Support Electrome’s scale-up with clean-room assembly, smart sensor integration, and flexible form factors.
2. Leadership Synergy via Sree Koneru
Koneru is currently Director of Program Management at Viant and also sits on BIEL’s Board of Directors. This dual role enables:
Seamless communication between engineering, regulatory, and executive teams.
Strategic alignment on product modernization, cost optimization, and clinical validation.
3. Technology Modernization Pathway
Viant’s capabilities could help BIEL and Electrome co-develop:
A smartphone-powered, battery-free, ultra-flexible version of RecoveryRx.
Devices inspired by recent PRFE bandage research, but with FDA-cleared foundations.
4. Equity and Investment Potential
Some investor speculation suggests Viant could become an equity stakeholder in BIEL, especially as BIEL trades near historical lows. This opens doors for:
Strategic investment by Electrome or Viant.
Joint ventures targeting global reimbursement markets and retail expansion.
5. Clinical and Regulatory Acceleration
Viant’s infrastructure supports:
Faster FDA and CE submissions.
Efficient clinical trial execution, especially for neuromodulation technologies.
6. Partnership Scenario: Triangular Collaboration
BIEL
IP holder and product originator
FDA-cleared tech, clinical data
Electrome
Innovation and market expansion
New applications, branding, distribution
Viant
Manufacturing and engineering partner
Scale-up, modernization, regulatory support
Sree Koneru acts as the linchpin, connecting technical, regulatory, and strategic dots across all three.
4
